Further to this earlier post, Health Canada has issued a safety update on TNF blockers and cancer in children and young adults. (Disclaimer: I work for Health Canada, but only in the correspondence unit.)
Labels: canada, drugs, side effects, tnf
A new study suggests that extracts from a Chinese medicinal plant, Tripterygium wilfordii, may be more effective in treating the symptoms of rheumatoid arthritis than sulfasalazine. While sulfasalazine may not be the first drug that comes to mind for inflammatory arthritis, I was on it for a while myself (when I was trying a few different treatments). Since the treatments for RA are usually directly applicable to ankylosing spondylitis, this may well have some implications for how our disease is treated down the road. The analogy that comes to mind is willow bark and acetylsalicylic acid (Aspirin).
Labels: drugs, research, traditional medicine
The U.S. Food and Drug Administration is requiring that TNF blockers have a warning added to their labels indicating an increased risk of cancer in children. "An analysis of U.S. reports of cancer in children and adolescents treated with TNF blockers showed an increased risk of cancer, occurring after 30 months of treatment on average. About half of the cancers were lymphomas, a type of cancer involving cells of the immune system. Some of the reported cancers were fatal." More information from Newsday, the Wall Street Journal and WebMD.
Labels: drugs, fda, side effects, tnf, usa
While there are generic equivalents of many chemically based drugs that cost patients a fraction of the brand-name cost (thanks, I suppose, to the original drug patents expiring), this is not the case for the high-cost biologics -- like Enbrel, Humira and Remicade -- that many of us are turning to for relief. That high cost is raising the question of how long brand-name biologics can be exempt from market competition from "biosimilar" or "biogeneric" drugs -- especially in the U.S., where the high cost of drugs and cost containment are a crucial part of the health coverage debate. The Chicago Tribune has the story.
I'm trying my best to step back a bit from the steady stream of news coming in about TNF-alpha blockers (i.e., biologics), because it can drown out everything else about our disease. But I have a selfish interest in the news that golimumab, which now has the trade name of Simponi, has been approved in Canada for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; it's apparently to be used in combination with methotrexate, and, like other biologics, it's indicated for AS when conventional (i.e., affordable) therapies have failed.
Previously: Golimumab and ankylosing spondylitis.
The Vancouver Sun reports that British Columbia's provincial prescription drug plan will cover adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) for patients with ankylosing spondylitis who meet the criteria of the plan's Special Authority program.
Update, March 8: Reaction from the Arthritis Society, which says that they and others have been lobbying the government for this decision for years.
Amazing what a change of government does. Saskatchewan's provincial drug plan now covers Enbrel and Humira for ankylosing spondylitis under Exception Drug Status coverage.
Update: CBC News coverage. Remicade wasn't approved because it costs more.
Previously: More about Saskatchewan's TNF coverage; Saskatchewan to AS patients: No biologics for you!
Fresh from going after Saskatchewan for its refusal to cover biologics for AS, Arthritis Consumer Experts is now turning its attention to the drug coverage provided to Aboriginal Canadians by the Non-Insured Health Benefits program of Health Canada's First Nations and Inuit Health Branch. Noted without comment -- I'm presently working on contract at Health Canada.
A follow-up article from the Regina Leader-Post on Saskatchewan's coverage of biologics -- they're covered for rheumatoid arthritis, two out of three are for psoriatic arthritis, but none for ankylosing spondylitis -- suggests, as an aside, that the newly elected Saskatchewan Party government may reverse the earlier decision not to approve coverage for AS. Indeed: why should our disease be treated, pun intended, differently?
Previously: Saskatchewan to AS patients: No biologics for you!
Label enhancements for infliximab (Remicade) have been approved by the European Commission for ankylosing spondylitis, Crohn's, and psoriatic arthritis, according to a press release: "The ankylosing spondylitis (AS) label indication has been broadened to include adults with severe active AS who have responded inadequately to conventional therapy. The label also includes a significant improvement in physical function and quality of life."
Meanwhile, a Canadian arthritis lobby group is fulminating against the Saskatchewan government, which last month decided against listing three TNF blockers -- presumably the big three, Enbrel, Humira and Remicade -- for the treatment of ankylosing spondylitis. This isn't about prescription drug coverage, says the group; it's about access, pure and simple: "As a result, people living in Saskatchewan with this inflammatory disease have absolutely no access to biologic medications to manage their disease." That seems a bit much. No access at all?
Update, 11/15: CBC News has more, including the Saskatchewan Formulary Committee's rationale: their position is that "the clinical benefit does not justify the incremental cost of these drugs." As a result of last week's provincial election, there will shortly be a change of government in Saskatchewan, so this decision may well be reversed.
Update, 11/18: More coverage from the province's main newspapers.
Britain's National Institute for Health and Clinical Excellence (NICE) has made a decision that restricts access to anti-TNF therapy by patients with severe ankylosing spondylitis, and the National Ankylosing Spondylitis Society (NASS) isn't happy about it. Only two out of three biologics will be accepted for use against ankylosing spondylitis: etanercept (Enbrel) and adalimumab (Humira), but not infliximab (Remicade). And Enbrel and Humira cannot be used sequentially -- which is to say that if you try Enbrel and it doesn't work, you can't then try Humira. And if neither works, you're SOL for Remicade. Cost is being cited: Remicade is more expensive to administer (since it can't be self-injected). See coverage from Channel 4, the Daily Mail, and This Is London.
As anyone with chronic inflammatory arthritis will tell you, it's impossible to tell what treatment will work in advance: I'm on naproxen, but I know AS patients who can't tolerate it; I know people who use indomethacin, but couldn't handle it myself. To have only one shot at anti-TNF therapy may make sense from a cost perspective, but it's lousy from the perspective of the person actually suffering from the disease.
Golimumab: another TNF-alpha antagonist for us to keep track of (I wonder what the trade name will be). According to a press release, "More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting."
At some point there will be as many biologics at our disposal as there currently are NSAIDs. Not that they'll be as cheap.
According to a study published in Arthritis and Rheumatism (abstract), TNF therapy is associated with an increased risk of skin cancer. The study examined 13,001 rheumatoid arthritis patients in clinical trials and compared their cancer rates with the general public. Via About.com Arthritis.
Labels: drugs, research, side effects, tnf
Arthritis Without Pain: The Miracle of TNF Blockers
by Scott J. Zashin, M.D. with M. Laurette Hesser
Rev. ed. Sarah Allison Publishing Company, 2004. Softcover, xiv + 261 pp. ISBN 0-9754060-0-0
Of the new TNF-alpha antagonists -- principally etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) -- that have generated so much attention in recent years and that have promised a revolution in the treatment of arthritic conditions, three things can be said. One, they're extremely expensive, costing thousands if not tens of thousands of dollars a year to administer. Two, they've been the subject of an intense marketing and media campaign on their behalf by the pharmaceutical companies, by doctors, and by advocates, who want as many people taking these new treatments and as many prescription drug plans covering them as possible. And three, from all accounts, they really do work.
The cost makes me blench, and the marketing makes me nervous. But there's a rationale behind both, and that is that these treatments are unlike anything else that we've taken before. They are far more complex to manufacture than traditional drugs, and they cannot be taken orally -- the digestive system would destroy the proteins before they hit the bloodstream -- and so must be administered by infusion or injection. They are, in other words, qualitatively different from any other arthritis treatment out there, and considerable explanation is therefore required.
There is therefore ample justification for a book such as Arthritis Without Pain: The Miracle of TNF Blockers, written by rheumatologist Scott J. Zashin with M. Laurette Hesser. While it suffers from the breathless "miracle-cure" rhetoric that I've seen before and that sets off my internal alarms, it does a respectable job of explaining what these treatments are, how they work, and how they fit in with other arthritis treatments out there. The detail is considerable, from how these treatments are administered, to how long they may take to take effect. And, to be sure, their potential side effects and drawbacks are mentioned as well.
Arthritis Without Pain was first published in 2000; this is the revised 2004 edition. But events have already overtaken things somewhat: Enbrel and Humira have since been approved for ankylosing spondylitis, for example. And it's primarily a book for people with rheumatoid arthritis; those of us with other rheumatic conditions for which these treatments are (now) indicated may be a little disappointed with that focus.
Another shortcoming too obvious to me as a copyeditor, but that most of you couldn't care less about: the book could frankly have been better written and better proofread. (Page 6: "More than 23 million Americans have [osteoarthritis]. Over one-third are women." Why that's more significant than the nearly two-thirds that are, presumably, men I have no idea.)
And is it truly necessary to use the ® symbol in every instance of a trade name? Style guides would not indicate so. But the fact that Zashin and Hessler cannot talk about Enbrel and Remicade, but only Enbrel® and Remicade®, may have something to do with the fact that Zashin has worked as a paid consultant for the companies involved. I would be more comfortable with reports about TNF antagonists that came from sources not so closely affiliated with the companies who made them.
Labels: book review, books, drugs, enbrel, humira, remicade, tnf
During a two-year clinical trial, the results of which were announced today, ankylosing spondylitis patients taking Remicade (infliximab) "experienced significant improvement in spinal mobility ... [and] showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging." The ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy) trial involved 279 patients, 78 of whom received a placebo. I'm assuming this is a company-sponsored study.
We've heard before about the difficulties British ankylosing spondylitis patients have had trying to get coverage for the latest (and presumably greatest) treatments, the expensive TNF-alpha blockers. This BBC News article affords some insight into the process by which an individual patient can have such treatments approved -- or denied:
The first business is two requests from patients with a painful rheumatic disease, ankylosing spondylitis.
They want drugs which cost £11,000 a year, but haven't yet been given the seal of approval by the health watchdog, the National Institute for Health and Clinical Excellence (NICE).
Other local patients might be eligible -- so the question is: are these exceptional cases?
"For a PCT our size, I guess we're looking at anywhere between 250 and 500 cases who may potentially benefit from this drug," said the public health director.
Another panel member said: "The doctor who's presented this says the severity of this patient's symptoms is unusual -- but that's not the same as exceptional.
"I guess for me it's the uncertainty about how this drug will affect this patient. Funding it would be a speculative move -- given the evidence we've got here."
Both requests are turned down.
For most of us, the medications we take to treat the pain and inflammation of ankylosing spondylitis are not addictive: the street value of naproxen, for example, is pretty low. But some of us have been prescribed opioids like oxycodone -- e.g., OxyContin and Percocet -- which are addictive. More addictive, in fact, than was previously let on: oxycodone's manufacturer, Purdue Frederick, and its executives were fined more than $634 million last month for understating the addictiveness of their drug. Now a class-action lawsuit may be in the offing in Canada, and a Cape Breton man with ankylosing spondylitis, who was prescribed Percocet, then OxyContin on top of that, and then turned to crime to feed his oxycodone habit, is interested in joining it, the Cape Breton Post reports (also reprinted in the Halifax Chronicle Herald).
Biotech drugs are helping pharmaceutical companies' bottom line because, unlike simple pharmaceuticals, biotech isn't subject to expiring patents. Pharmaceutical companies can lose billions in income when a drug patent expires, though we benefit when a cheaper generic equivalent hits the market. So biotech's profit potential is much greater, because it is -- at least for now -- more or less perpetual.
Why is this of interest? Because biotech includes TNF-alpha blockers like Enbrel, Humira and Remicade. (Humira is specifically mentioned in the article: it contributes $2 billion, or nearly 10 per cent, to Abbott's bottom line.) And these are the drugs that we, as ankylosing spondylitis patients, are increasingly being put on.
We know we're being marketed to about these drugs. To what extent is these drugs' extreme profitability playing a role in getting us on them? It's hard to think objectively about these drugs in this context. They may well be better. But I can't help but wonder if the industry would prefer it if I (or my spouse's drug plan) was spending $1,500 on a biologic, rather than $30 a month on generic naproxen.
The Arthritis Society is campaigning to raise the profile of arthritis patients during the upcoming provincial election in Prince Edward Island. Notably, they point to how long it takes the provincial drug plan to approve drugs: approvals for biologics lag behind other provinces, and even Celebrex isn't covered. Don't miss the boneheaded responses from the provincial parties that sidestep the question and talk about disease prevention and lifestyle choices: when you've got an inflammatory autoimmune disease, it's already too late for that, and you don't catch what we have from eating too many Ding-Dongs, you assclowns.
Labels: canada, celebrex, coverage, cox-2, drugs, enbrel, humira
As a result, I think, of the European Union's approval of Celebrex (celecoxib) to treat ankylosing spondylitis, the drug has now been granted a label extension for treating AS in the UK, Pfizer announced in a media release yesterday.
The Salisbury Journal has another one of those articles about an ankylosing spondylitis patient who, having taken Remicade (infliximab), has made a dramatic turnaround: "After I had the treatment, I was out of the hospital like an athlete, I was told it could take several weeks to work but it was amazing and worked straight away," the article quotes the unfortunately named Mark Weakly. "It's like a miracle cure."
As you may know, I've seen a lot of stories like these in the British press.
More bad news for Merck: an FDA panel voted against approving Arcoxia (etoricoxib), a COX-2 inhibitor touted as a successor to Vioxx: "Expressing concern over the cardiac safety of Arcoxia, the FDA panel voted 20 to 1, opposing the approval of the drug." The FDA's final decision comes on April 27.
Previously: Arcoxia better than naproxen?
An auto-injector for Enbrel (etanercept) is now available in Canada, which should make it easier for patients to administer their own meds. As someone averse to needles, I can appreciate this.
In November 2005 I referred to a Vioxx lawsuit that Merck won in New Jersey. A superior court judge granted the plaintiffs -- Frederick "Mike" Humeston and his wife Mary, of Idaho -- a new trial based on new evidence about the risks of short-term Vioxx use, and today the jury in the second trial returned a very different outcome from the first trial: they awarded the Humestons a total of $47.5 million in compensatory and punitive damages. AP story: Business Week; Houston Chronicle; Wired. Merck is facing 28,000 lawsuits over Vioxx (half of them in New Jersey), and they're fighting them one by one; they say they'll appeal.
Meanwhile, an announcement that will no doubt amuse those of you who've been using it to treat your ankylosing spondylitis for years, the European Union has approved Celebrex (celecoxib) for the treatment of ankylosing spondylitis in adults. I'm surprised to discover that this is actually the first time a COX-2 drug has been approved for AS by the European Union.
British Columbia's provincial drug plan doesn't cover Remicade (infliximab) for ankylosing spondylitis, though it's been approved for rheumatoid arthritis and Crohn's disease, reports The Peace Arch News, leaving AS sufferers (or, presumably, their private plans) to pick up the full $24,000 tab if they want the newer treatment.
One interesting bit from the article encapsulates the problem with B.C.'s prescription drug coverage: "B.C. pays more for generic drugs than other provinces; and, B.C. is usually last to approve new medications. One drug, Enbrel, for the treatment of psoriatic arthritis, has been under study and review here for more than three years. Meanwhile, it’s approved for use in every other province except Prince Edward Island." Of course, Enbrel (etanercept) is of interest to AS sufferers too.
Don't for a moment forget that when it comes to the biologic (aka TNF-alpha) treatments for ankylosing spondylitis, we are being marketed to: a total of $195 million was spent to market five biologics in the U.S., France and Germany -- direct-to-patient ads in the U.S. ("ask your doctor") only, doctor- and industry-targeted ads throughout. Keep that in mind when reading news coverage about this stuff, because frequently the boundary between PR and news is quite tenuous.
Pharmaceutical company Amgen announced long-term results for Enbrel (etanercept): after three years, they report, 59 patients in their clinical trial "experienced sustained improvement in signs and symptoms, spinal mobility and physical function." Of that 59, 46 experienced at least 20 per cent improvement, and 18 achieved partial remission. Business Week; press release (reprinted here and here).
It's interesting to see longer-term data on the new anti-TNF treatments, especially in the context of some anecdotal reports of them not working for people after a while.
Pharmaceutical company Abbot announced today that Humira (adalimumab) has now been approved by Health Canada for the treatment of ankylosing spondylitis. It's already been approved for AS in the U.S. and Europe, and it's already been approved in Canada for rheumatoid arthritis and psoriatic arthritis.
Dr, Thomas Stuttaford, whom we last saw in a June 2005 writing a Times article about TNF-alpha inhibitors, is back in the Times with an article about ankylosing spondylitis -- and the effectiveness of the new TNF-alpha inhibitors in treating it. (I sense a trend.) Talks about the drugs' use and availability in the UK and mentions which pharaohs had AS, so it's a pretty broad-ranging article.
Ankylose This! is a group blog about life with ankylosing spondylitis. Its authors post about their own experiences, medical news, and useful resources.
Disclaimer: None of us are doctors, and nothing in this blog should be construed as medical advice. We are simply patients trying to make sense of our disease.
